Immix Biopharma, Inc. (IMMX) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2024. Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor (CAR-T) cell therapies, primarily for AL Amyloidosis and select immune-mediated diseases. The Company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. In May 2024, the Company completed the absorption of its majority-owned subsidiary, Nexcella, Inc., into the parent company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(7,149,395) | $(4,343,912) | $(16,886,309) | $(10,440,156) |
| Loss Per Share (Basic/Diluted) | $(0.24) | $(0.23) | $(0.60) | $(0.65) |
| Cash and Cash Equivalents (End of Period) | $19,690,431 (as of Sept 30, 2024) | |||
| Working Capital | $16,191,004 (as of Sept 30, 2024) | |||
| Accumulated Deficit | $(70,212,617) (as of Sept 30, 2024) | |||
| Operating Cash Flow (YTD) | $(13,118,904) | $(8,694,001) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses for the nine months ended September 30, 2024, were $17.7 million, a 64% increase from $10.8 million in the prior year period.
- Research & Development (R&D): Increased to $9.9 million (YTD 2024) from $5.6 million (YTD 2023), driven by costs associated with ongoing Phase 1b/2a clinical trials, CRO fees, and license fees.
- General & Administrative (G&A): Increased to $7.8 million (YTD 2024) from $5.1 million (YTD 2023), primarily due to increased investor relations services ($1.2M), higher compensation costs, and increased stock-based compensation.
- Capital Raising: In February 2024, the Company completed an underwritten public offering and full exercise of the over-allotment option, raising net proceeds of approximately $15.5 million. The Company also raised $338,495 via its ATM facility prior to suspending it in February 2024.
- Asset Acquisition: The Company entered into a long-term operating lease for 14,000 square feet of biopharmaceutical manufacturing space in January 2024, resulting in a Right-of-Use asset of $1.0 million and related liabilities.
- Interest Income: Interest income increased to $831,503 (YTD 2024) from $343,431 (YTD 2023) due to higher cash balances invested in money market funds.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: Management believes existing cash of approximately $19.7 million, combined with potential funds from the CIRM grant, will fund operations for at least the next 12 months. However, the Company has a history of losses and will require additional capital to advance clinical trials and commercialization.
- CIRM Grant: On July 25, 2024, the Company was awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for the development of NXC-201. Funds are milestone-based (primarily patient enrollment) and expected to begin disbursing in November 2024. There is a risk that funds may not be received if milestones are not met or terms are not complied with.
- Clinical Progress: As of September 2024, the Company has treated 3 patients in the U.S. Phase 1b/2 trial (NEXICART-2) and 13 patients in the ex-U.S. trial (NEXICART-1). NXC-201 holds Orphan Drug Designation from both the FDA and EMA.
- Internal Controls: The Company identified a material weakness in internal controls over financial reporting related to segregation of duties and review processes due to its small size. This weakness existed as of December 31, 2023, and remained as of September 30, 2024. Management is implementing remediation plans.
- Risk Factors: Key risks include the need for substantial additional capital, the uncertainty of clinical trial results, dependence on third-party manufacturers, and potential dilution from future equity offerings.
Investor Verification Checklist
- Cash Runway: Verify the specific monthly burn rate and confirm the 12-month liquidity projection given the high R&D spend.
- CIRM Grant Terms: Review the specific milestones required to unlock the $8 million CIRM grant and the probability of achieving patient enrollment targets on time.
- Internal Control Remediation: Monitor the Company's progress in addressing the material weakness in internal controls over financial reporting.
- Dilution Risk: Assess the impact of outstanding options (4.0 million shares) and warrants (2.3 million shares) on future share count and ownership dilution.
- Clinical Data: Await further data readouts from the NEXICART-1 and NEXICART-2 trials to validate the 100% overall response rate previously reported.